Dalrada unit Genefic terminates IBS financing agreements for up to $25 million facilities

• Dalrada unit Genefic terminated financing agreements with IBS Fund III, IBS Fund IV; IBS treated Sept. 15, 2026 as early termination.
• Facilities covered a standby letter of credit and guaranty commitment up to $20 million, plus a credit and account purchase facility up to $5 million.
• IBS provided no funding under the arrangements; no loans, advances, or receivables purchases occurred; no letter of credit was drawn.
• IBS asserted termination does not release obligations or security until claimed amounts are paid; early termination fees are disputed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dalrada Technology Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007291), on September 22, 2026, and is solely responsible for the information contained therein.